We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AFMD
101
DELISTED
Affimed
AFMD
$869K 0.03%
66,821
– –
GRDX
102
GridAI Technologies Corp
GRDX
$18.3M
$841K 0.03%
2
– –
RXDX
103
DELISTED
Ignyta, Inc.
RXDX
$807K 0.03%
+30,211
New +$491K
ALGN icon
104
Align Technology
ALGN
$12.9B
$766K 0.03%
3,448
– –
ADYX
105
DELISTED
Adynxx Inc
ADYX
$766K 0.03%
70,566
– –
ARNA
106
DELISTED
Arena Pharmaceuticals Inc
ARNA
$747K 0.02%
+21,978
New +$626K
SCMP
107
DELISTED
Sucampo Pharmaceuticals, Inc.
SCMP
$719K 0.02%
+40,062
New +$493K
ESPR
108
DELISTED
Esperion Therapeutics
ESPR
$709K 0.02%
10,769
– –
CNC icon
109
Centene
CNC
$30.5B
$676K 0.02%
13,398
-2,054
-13% -$99.5K
CRIS icon
110
Curis
CRIS
$9.71M
$666K 0.02%
476
– –
RACE icon
111
Ferrari
RACE
$67.8B
$650K 0.02%
6,200
– –
TARA icon
112
Protara Therapeutics
TARA
$214M
$635K 0.02%
8,353
– –
BHC icon
113
Bausch Health
BHC
$1.75B
$625K 0.02%
+30,092
New +$477K
EVH icon
114
Evolent Health
EVH
$371M
$615K 0.02%
50,000
-800,000
-94% -$11.3M
SPPI
115
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$609K 0.02%
+32,154
New +$582K
XBI icon
116
PUT
State Street SPDR S&P Biotech ETF
XBI
$10B
$579K 0.02%
+600,000
New +$50.3M
ONC
117
BeOne Medicines Ltd
ONC
$33.9B
$557K 0.02%
5,700
– –
CUTR
118
DELISTED
Cutera, Inc.
CUTR
$543K 0.02%
11,981
– –
MRTX
119
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$531K 0.02%
+29,091
New +$451K
VRAY
120
DELISTED
ViewRay, Inc.
VRAY
$463K 0.02%
+50,000
New +$400K
HCM icon
121
HUTCHMED
HCM
$1.96B
$394K 0.01%
10,000
– –
KERX
122
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$388K 0.01%
83,386
– –
PGNX
123
DELISTED
Progenics Pharmaceuticals Inc
PGNX
$368K 0.01%
+61,850
New +$376K
SENS icon
124
Senseonics Holdings Inc
SENS
$254M
$306K 0.01%
5,750
+3,250
+130% +$181K
CASI
125
DELISTED
CASI Pharmaceuticals
CASI
$272K 0.01%
+8,368
New +$227K
3 4
5
6 7

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.